HPSI0913i-diku_1
WTSIi009-A
General
Cell Line |
|
hPSCreg name | WTSIi009-A |
Cite as: | WTSIi009-A (RRID:CVCL_AH28) |
Alternative name(s) |
HPSI0913i-diku_1
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 26th July 2019 |
User feedback | |
Provider |
|
Generator | Wellcome Sanger Institute (WTSI) |
Distributors | |
Derivation country | United Kingdom |
External Databases |
|
BioSamples | SAMEA2593858 |
HipSci | HPSI0913i-diku_1 |
Cellosaurus | CVCL_AH28 |
Wikidata | Q54891443 |
General Information |
|
Publications | |
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclones |
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 60-64 |
Ethnicity | White - White British |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA2398076 |
HipSci | HPSI-diku |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | HipSci (http://www.hipsci.org/) |
Is there other documentation provided to the donor for consenting purposes? | Yes |
Has the donor agreed to be re-contacted? | No |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | Yes |
Please describe how access is provided: | |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | NRES Committee Yorkshire & The Humber - Leeds West |
Approval number | 15/YH/0391 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | NRES Committee Yorkshire & The Humber - Leeds West |
Approval number | 15/YH/0391 |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Age of donor (at collection) | 60-64 |
Collected in | 2014 |
Source cell line vendor | Cambridge BioResource |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Notes on reprogramming vector detection | CytoTune 1 |
Vector free reprogramming |
|
Other |
|
Selection criteria for clones | Morphology |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Vitronectin |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
CO2 Concentration | 5 % |
Medium |
TeSR™ E8™
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
|
|||
SOX2 |
Yes |
|
||||
NANOG |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
SSEA-1 |
No |
|
||||
TRA 1-60 |
Yes |
|
Pluripotency Score | Novelty Score | Link to microarray data |
28.091 | 1.259 | http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4057/ |
Report
HPSI-diku.pluritest.pluripotency_score.20161010.png
pluripotency image
HPSI-diku.pluritest.novelty_score.20161010.png
novelty image
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Certificate of Analysis |
|
Is there a certificate of analysis available? |
Yes
Passage:
28
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
http://www.ebi.ac.uk/ena/data/view/ERZ123023
cnv
http://www.hipsci.org/lines/#/lines/HPSI0913i-diku_1 Number of regions different from primary tissue: 0; Length of differences from primary tissue: 0
Methylation profiling
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4059/ Text file with probe intensities
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755 This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768 |
Login to share your feedback, experiences or results with the research community.